AAAAAA

   
Results: 1-10 |
Results: 10
How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease? Response to Egede
Authors: Grover, SA Coupal, L Zowall, H
Citation: Sa. Grover et al., How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease? Response to Egede, DIABET CARE, 24(7), 2001, pp. 1306-1307
How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease?
Authors: Grover, SA Coupal, L Zowall, H Alexander, CM Weiss, TW Gomes, DRJ
Citation: Sa. Grover et al., How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease?, DIABET CARE, 24(1), 2001, pp. 45-50
Lipid screening to prevent coronary artery disease: a quantitative evaluation of evolving guidelines
Authors: Grover, SA Dorais, M Paradis, G Fodor, JG Frohlich, JJ McPherson, R Coupal, L Zowall, H
Citation: Sa. Grover et al., Lipid screening to prevent coronary artery disease: a quantitative evaluation of evolving guidelines, CAN MED A J, 163(10), 2000, pp. 1263-1269
The clinical burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model
Authors: Grover, SA Coupal, L Zowall, H Rajan, R Trachtenberg, J Elhilali, M Chetner, M Goldenberg, L
Citation: Sa. Grover et al., The clinical burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model, CAN MED A J, 162(7), 2000, pp. 977-983
The economic burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model
Authors: Grover, SA Coupal, L Zowall, H Rajan, R Trachtenberg, J Elhilali, M Chetner, M Goldenberg, L
Citation: Sa. Grover et al., The economic burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model, CAN MED A J, 162(7), 2000, pp. 987-992
Cost-effectiveness of treating hyperlipidemia in the presence of diabetes - Who should be treated?
Authors: Grover, SA Coupal, L Zowall, H Dorais, M
Citation: Sa. Grover et al., Cost-effectiveness of treating hyperlipidemia in the presence of diabetes - Who should be treated?, CIRCULATION, 102(7), 2000, pp. 722-727
Impact of treating hyperlipidemia or hypertension to reduce the risk of death from coronary artery disease. (vol 160, pg1449, 1999)
Authors: Perreault, S Dorais, M Coupal, L Paradis, G Joffres, MR Grover, SA
Citation: S. Perreault et al., Impact of treating hyperlipidemia or hypertension to reduce the risk of death from coronary artery disease. (vol 160, pg1449, 1999), CAN MED A J, 161(1), 1999, pp. 21-21
Prostate cancer: 12. The economic burden
Authors: Grover, SA Zowall, H Coupal, L Krahn, MD
Citation: Sa. Grover et al., Prostate cancer: 12. The economic burden, CAN MED A J, 160(5), 1999, pp. 685-690
Impact of treating hyperlipidemia or hypertension to reduce the risk of death from coronary artery disease
Authors: Perreault, S Dorais, M Coupal, L Paradis, G Joffres, MR Grover, SA
Citation: S. Perreault et al., Impact of treating hyperlipidemia or hypertension to reduce the risk of death from coronary artery disease, CAN MED A J, 160(10), 1999, pp. 1449-1455
Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease - Forecasting the incremental benefits of preventing coronary and cerebrovascular events
Authors: Grover, SA Coupal, L Paquet, S Zowall, H
Citation: Sa. Grover et al., Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease - Forecasting the incremental benefits of preventing coronary and cerebrovascular events, ARCH IN MED, 159(6), 1999, pp. 593-600
Risultati: 1-10 |